Font

Aa Aa Aa

Background color

A A

Site version

Color Black and white
Drugs

Amiodarone-Darnitsa

Class III antiarrhythmic agents

Composition. Active substance: amiodarone.

Preventing recurrence of:

– Life-threatening ventricular tachycardia (Amiodarone-Darnitsa can only be administered in a hospital setting under observation)
– Documented symptomatic and disabling ventricular tachycardia
– Documented supraventricular tachycardia, if the need to prescribe the drug is established in patients with a condition that is resistant to other therapies or with contraindications to other methods of treating ventricular fibrillation

Treatment of supraventricular tachycardia: slowing or reducing atrial fibrillation or flutter.

Amiodarone can be used in patients with ischemic heart disease and/or left ventricular dysfunction (see the Pharmacodynamics Section).

In adults, the drug is taken orally, during or after a meal, without chewing, with a small amount of liquid.

Initial treatment.

The usual dosing regimen is 3 tablets per day for 8 to 10 days.

In some cases, higher doses can be used for initial treatment (4 to 5 tablets per day), but always for a short period and under ECG monitoring.

Maintenance treatment.

The minimum effective dose should be determined; it may vary depending on the patient from 0.5 tablets per day (1 tablet per 2 days) to 2 tablets per day.

Children.

The safety and efficacy of amiodarone in children have not been assessed, so using the drug in children is not recommended.

Specialized edition for medical institutions and doctors.